Biomarker solutions to accelerate global clinical trials

Molecular Insights— base by base, from target discovery to commercial launch.

We are applying our expertise in genomic profiling to identify elusive cancer-related genetic changes and new biomarker targets across many cancer types. Our advanced cancer genome analysis helps researchers and biopharmaceutical partners accelerate new precision medicine development.

Comprehensive support for biomarker-driven drug development

We support genomic profiling of Phase I-III clinical trial samples in our CLIA-certified and CAP-accredited laboratories utilizing our panel of comprehensive molecular profiling assays.

CLINICAL APPLICATIONS

Liquid biopsy for treatment selection, disease monitoring, and MRD detection

Molecular profiling

One panel does not fit all

We offer a portfolio of comprehensive genomic profiling assays for precision medicine development.

Immuno-oncology and biomarker solutions

  • TMB
  • MSI
  • PDL1 (CNV, SV)
PredicineATLAS™

DNA damage repair and clinical solutions

  • BRCA1/2
  • ATM
  • FGFR1/2/3/4
PredicineCARE™

Fusion and splicing RNA solutions

  • NTRK1/2/3
  • AR
  • MET
PredicineRNA™

CROSS-BORDER TRIALS

Harmonized assay with unified workflow in U.S. and China for cross-border trials

We provide harmonized assays supported by unified quality management systems and workflow in our network of CLIA-certified and CAP-accredited facilities in U.S. and China to support cross-border clinical studies.

Get in touch

Ready to streamline your precision oncology clinical research programs? Submit your information to speak to a team member.